{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T04:26:01Z","timestamp":1773721561838,"version":"3.50.1"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,15]],"date-time":"2021-10-15T00:00:00Z","timestamp":1634256000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013385","name":"National Science and Technology Program during the Twelfth Five-year Plan Period","doi-asserted-by":"publisher","award":["2017ZX09304014"],"award-info":[{"award-number":["2017ZX09304014"]}],"id":[{"id":"10.13039\/501100013385","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81302850"],"award-info":[{"award-number":["81302850"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81974513"],"award-info":[{"award-number":["81974513"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002822","name":"Central South University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002822","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Advanced Research"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.jare.2021.10.004","type":"journal-article","created":{"date-parts":[[2021,10,19]],"date-time":"2021-10-19T09:34:48Z","timestamp":1634636088000},"page":"319-332","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Gut microbiota and host Cyp450s co-contribute to pharmacokinetic variability in mice with non-alcoholic steatohepatitis: Effects vary from drug to drug"],"prefix":"10.1016","volume":"39","author":[{"given":"Jing","family":"Guo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-jie","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Song-xia","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-ligh","family":"Liou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-ping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi-rong","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong-hao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jare.2021.10.004_b0005","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.cgh.2014.01.035","article-title":"One size fits one: pharmacogenetics in gastroenterology","volume":"12","author":"Porayette","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jare.2021.10.004_b0010","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2174\/138920007779816002","article-title":"Pharmacokinetic and pharmacodynamic variability: a daunting challenge in drug therapy","author":"Lin","year":"2007","journal-title":"Curr Drug Metab"},{"key":"10.1016\/j.jare.2021.10.004_b0015","first-page":"1","article-title":"Influence factors of the pharmacokinetics of herbal resourced compounds in clinical practice","volume":"2019","author":"Sun","year":"2019","journal-title":"Evid Based Complement Alternat Med"},{"key":"10.1016\/j.jare.2021.10.004_b0020","doi-asserted-by":"crossref","unstructured":"Kulkarni NM, Malampati S, Mahat MY, Chandrasekaran S, Raghul J, Khan AA et al. Altered pharmacokinetics of rosiglitazone in a mouse model of non-alcoholic fatty liver disease. Drug Metab Pers Ther 2016;165\u201371. doi: 10.1515\/dmpt-2016-0008.","DOI":"10.1515\/dmpt-2016-0008"},{"key":"10.1016\/j.jare.2021.10.004_b0025","doi-asserted-by":"crossref","unstructured":"ter Heine R, Binkhorst L, de Graan AJ, de Bruijn P, Beijnen JH, Mathijssen RH, et al. Population pharmacokinetic modelling to assess the impact of CYP2D6 and CYP3A metabolic phenotypes on the pharmacokinetics of tamoxifen and endoxifen, Br J Clin Pharmacol. 2014;572-86. doi: 10.1111\/bcp.12388.","DOI":"10.1111\/bcp.12388"},{"issue":"2","key":"10.1016\/j.jare.2021.10.004_b0030","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/sj.clpt.6100275","article-title":"Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics","volume":"83","author":"Shu","year":"2008","journal-title":"Clin Pharmacol Ther."},{"key":"10.1016\/j.jare.2021.10.004_b0035","doi-asserted-by":"crossref","unstructured":"Koukoula M, Dotsikas Y, Molou E, Schulpis KH, Thodi G, Chatzidaki M et al. Study of the effect of CYP2C19 polymorphisms on omeprazole pharmacokinetics by utilizing validated LC-MS\/MS and Real Time-PCR methods. J Chromatogr B Analyt Technol Biomed Life Sci. 2017;173\u2013179. doi:10.1016\/j.jchromb.2016.06.046.","DOI":"10.1016\/j.jchromb.2016.06.046"},{"key":"10.1016\/j.jare.2021.10.004_b0040","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.phrs.2018.01.019","article-title":"The role of gut microbiota in the pharmacokinetics of antihypertensive drugs","volume":"130","author":"Choi","year":"2018","journal-title":"Pharmacol Res"},{"issue":"4","key":"10.1016\/j.jare.2021.10.004_b0045","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/nrmicro2974","article-title":"The gut microbiota\u2013masters of host development and physiology","volume":"11","author":"Sommer","year":"2013","journal-title":"Nat Rev Microbiol"},{"issue":"2","key":"10.1016\/j.jare.2021.10.004_b0050","first-page":"94","article-title":"Preimmune recognition and response to microbial metabolites","volume":"36","author":"Neish","year":"2021","journal-title":"Physiology (Bethesda)"},{"key":"10.1016\/j.jare.2021.10.004_b0055","doi-asserted-by":"crossref","unstructured":"Sender R, Fuchs S, Milo R. Revised Estimates for the Number of Human and Bacteria Cells in the Body, PLoS Biol 2016;e1002533. doi: 10.1371\/journal.pbio.1002533.","DOI":"10.1101\/036103"},{"issue":"6427","key":"10.1016\/j.jare.2021.10.004_b0060","doi-asserted-by":"crossref","DOI":"10.1126\/science.aat9931","article-title":"Separating host and microbiome contributions to drug pharmacokinetics and toxicity","volume":"363","author":"Zimmermann","year":"2019","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.jare.2021.10.004_b0065","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1111\/cts.12785","article-title":"Enhanced characterization of drug metabolism and the influence of the intestinal microbiome: a pharmacokinetic, microbiome, and untargeted metabolomics study","volume":"13","author":"Jarmusch","year":"2020","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.jare.2021.10.004_b0070","doi-asserted-by":"crossref","unstructured":"Johnson CH, Patterson AD, Idle JR, Gonzalez FJ. Xenobiotic metabolomics: major impact on the metabolome, Annu Rev Pharmacol Toxicol 2012;37\u201356. doi: 10.1146\/annurev-pharmtox-010611-134748.","DOI":"10.1146\/annurev-pharmtox-010611-134748"},{"issue":"1","key":"10.1016\/j.jare.2021.10.004_b0075","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/mnfr.201200461","article-title":"Role of intestinal microflora in xenobiotic-induced toxicity","volume":"57","author":"Jeong","year":"2013","journal-title":"Mol Nutr Food Res"},{"issue":"7","key":"10.1016\/j.jare.2021.10.004_b0080","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1016\/j.apsb.2020.09.013","article-title":"The influence of the gut microbiota on the bioavailability of oral drugs","volume":"11","author":"Zhang","year":"2021","journal-title":"Acta Pharm Sin B"},{"issue":"5778","key":"10.1016\/j.jare.2021.10.004_b0085","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1126\/science.1124234","article-title":"Metagenomic analysis of the human distal gut microbiome","volume":"312","author":"Gill","year":"2006","journal-title":"Science"},{"issue":"12","key":"10.1016\/j.jare.2021.10.004_b0090","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1007\/s12272-017-0986-y","article-title":"Impact of gut microbiota on drug metabolism: an update for safe and effective use of drugs","volume":"40","author":"Noh","year":"2017","journal-title":"Arch Pharm Res"},{"issue":"3","key":"10.1016\/j.jare.2021.10.004_b0095","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s12272-013-0179-2","article-title":"Role of metabolism by intestinal microbiota in pharmacokinetics of oral baicalin","volume":"37","author":"Kang","year":"2014","journal-title":"Arch Pharm Res"},{"key":"10.1016\/j.jare.2021.10.004_b0100","doi-asserted-by":"crossref","unstructured":"Matuskova Z, Anzenbacherova E, Vecera R, Tlaskalova-Hogenova H, Kolar M, Anzenbacher P. Administration of a probiotic can change drug pharmacokinetics: effect of E. coli Nissle 1917 on amidarone absorption in rats, PLoS One. 2014;e87150. doi:10.1371\/journal.pone.0087150.","DOI":"10.1371\/journal.pone.0087150"},{"key":"10.1016\/j.jare.2021.10.004_b0105","article-title":"Chemical reaction vector embeddings: towards predicting drug metabolism in the human gut microbiome","volume":"56\u201367","author":"Mallory","year":"2018","journal-title":"Pac Symp Biocomput"},{"issue":"14","key":"10.1016\/j.jare.2021.10.004_b0110","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1056\/NEJM198110013051403","article-title":"Inactivation of digoxin by the gut flora: reversal by antibiotic therapy","volume":"305","author":"Lindenbaum","year":"1981","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jare.2021.10.004_b0115","doi-asserted-by":"crossref","first-page":"233","DOI":"10.4161\/gmic.27915","article-title":"Mechanistic insight into digoxin inactivation by Eggerthella lenta augments our understanding of its pharmacokinetics","volume":"5","author":"Haiser","year":"2014","journal-title":"Gut Microbes"},{"issue":"7","key":"10.1016\/j.jare.2021.10.004_b0120","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman","year":"2018","journal-title":"Nat Med"},{"issue":"11","key":"10.1016\/j.jare.2021.10.004_b0125","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1111\/jgh.15005","article-title":"Effects of constant light exposure on sphingolipidomics and progression of NASH in high-fat-fed rats","volume":"35","author":"Yue","year":"2020","journal-title":"J Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.jare.2021.10.004_b0130","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s12072-019-10001-4","article-title":"New drugs for NAFLD: lessons from basic models to the clinic","volume":"14","author":"Reimer","year":"2020","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jare.2021.10.004_b0135","doi-asserted-by":"crossref","unstructured":"Suzuki A, Diehl AM. Nonalcoholic Steatohepatitis, Annu Rev Med.(2017) 85-98. doi:10.1146\/annurev-med-051215-031109.","DOI":"10.1146\/annurev-med-051215-031109"},{"key":"10.1016\/j.jare.2021.10.004_b0140","doi-asserted-by":"crossref","unstructured":"Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology, Gastroenterology 2012;1592\u2013609. doi: 10.1053\/j.gastro.2012.04.001.","DOI":"10.1053\/j.gastro.2012.04.001"},{"key":"10.1016\/j.jare.2021.10.004_b0145","doi-asserted-by":"crossref","first-page":"665","DOI":"10.3389\/fendo.2019.00665","article-title":"Inhibiting ceramide synthesis attenuates hepatic steatosis and fibrosis in rats with non-alcoholic fatty liver disease","author":"Jiang","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"5","key":"10.1016\/j.jare.2021.10.004_b0150","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1007\/s10620-016-4143-0","article-title":"Global epidemiology of nonalcoholic fatty liver disease and perspectives on US minority populations","volume":"61","author":"Sherif","year":"2016","journal-title":"Dig Dis Sci."},{"key":"10.1016\/j.jare.2021.10.004_b0155","doi-asserted-by":"crossref","unstructured":"Zhou J, Zhou F, Wang W, Zhang XJ, Ji YX, Zhang P et al. Epidemiological Features of NAFLD From 1999 to 2018 in China, Hepatology 2020;1851\u20131864. doi: 10.1002\/hep.31150.","DOI":"10.1002\/hep.31150"},{"issue":"1","key":"10.1016\/j.jare.2021.10.004_b0160","doi-asserted-by":"crossref","DOI":"10.1186\/s12944-021-01520-x","article-title":"Sirtuin3 rs28365927 functional variant confers to the high risk of non-alcoholic fatty liver disease in Chinese Han population","volume":"20","author":"Chen","year":"2021","journal-title":"Lipids Health Dis"},{"issue":"3","key":"10.1016\/j.jare.2021.10.004_b0165","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1007\/s00535-017-1415-1","article-title":"Current and future pharmacological therapies for NAFLD\/NASH","volume":"53","author":"Sumida","year":"2018","journal-title":"J Gastroenterol"},{"issue":"2","key":"10.1016\/j.jare.2021.10.004_b0170","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.jhep.2017.10.015","article-title":"Pharmacotherapy for NASH: current and emerging","volume":"68","author":"Konerman","year":"2018","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.jare.2021.10.004_b0175","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1080\/03602532.2017.1293683","article-title":"Non-alcoholic fatty liver disease (NAFLD) - pathogenesis, classification, and effect on drug metabolizing enzymes and transporters","volume":"49","author":"Cobbina","year":"2017","journal-title":"Drug Metab Rev"},{"issue":"8","key":"10.1016\/j.jare.2021.10.004_b0180","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1053\/j.gastro.2016.02.066","article-title":"Pathogenesis of nonalcoholic steatohepatitis","volume":"150","author":"Machado","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jare.2021.10.004_b0185","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1097\/MOG.0000000000000349","article-title":"Intestinal microbiota and nonalcoholic steatohepatitis","author":"Brandl","year":"2017","journal-title":"Curr Opin Gastroenterol"},{"key":"10.1016\/j.jare.2021.10.004_b0190","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201809302","article-title":"The role of the microbiome in NAFLD and NASH","author":"Kolodziejczyk","year":"2019","journal-title":"EMBO Mol Med"},{"issue":"4","key":"10.1016\/j.jare.2021.10.004_b0195","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/cpt.66","article-title":"Altered morphine glucuronide and bile acid disposition in patients with nonalcoholic steatohepatitis","volume":"97","author":"Ferslew","year":"2015","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.jare.2021.10.004_b0200","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.jhep.2019.10.003","article-title":"The gut-liver axis in liver disease: Pathophysiological basis for therapy","volume":"72","author":"Albillos","year":"2020","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.jare.2021.10.004_b0205","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/bmc.3003","article-title":"A high-throughput inhibition screening of major human cytochrome P450 enzymes using an in vitro cocktail and liquid chromatography-tandem mass spectrometry","volume":"28","author":"Qin","year":"2014","journal-title":"Biomed Chromatogr"},{"key":"10.1016\/j.jare.2021.10.004_b0210","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1067\/mcp.2003.14","article-title":"Isozyme-specific induction of low-dose aspirin on cytochrome P450 in healthy subjects","author":"Chen","year":"2003","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jare.2021.10.004_b0215","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1515\/dmdi-2012-0002","article-title":"Cytochrome P450 enzymes","author":"Meyer","year":"2012","journal-title":"Drug Metabol Drug Interact"},{"issue":"20","key":"10.1016\/j.jare.2021.10.004_b0220","doi-asserted-by":"crossref","first-page":"4875","DOI":"10.1007\/s00216-014-7915-4","article-title":"Phenotyping of CYP450 in human liver microsomes using the cocktail approach","volume":"406","author":"Spaggiari","year":"2014","journal-title":"Anal Bioanal Chem"},{"issue":"3","key":"10.1016\/j.jare.2021.10.004_b0225","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s00394-017-1524-x","article-title":"Influence of gut microbiota on the development and progression of nonalcoholic steatohepatitis","volume":"57","author":"de Faria Ghetti","year":"2018","journal-title":"Eur J Nutr"},{"key":"10.1016\/j.jare.2021.10.004_b0230","doi-asserted-by":"crossref","first-page":"692","DOI":"10.2174\/138920009789895543","article-title":"Cytochrome p450 and steatosis","author":"G\u00f3mez-Lech\u00f3n","year":"2009","journal-title":"Curr Drug Metab"},{"key":"10.1016\/j.jare.2021.10.004_b0235","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.taap.2018.05.021","article-title":"Investigation of nonalcoholic fatty liver disease-induced drug metabolism by comparative global toxicoproteomics","volume":"352","author":"Na","year":"2018","journal-title":"Toxicol Appl Pharmacol"},{"issue":"2","key":"10.1016\/j.jare.2021.10.004_b0240","doi-asserted-by":"crossref","first-page":"e21840","DOI":"10.1002\/jbt.21840","article-title":"In vivo cytochrome P450 activity alterations in diabetic nonalcoholic steatohepatitis mice","volume":"31","author":"Li","year":"2017","journal-title":"J Biochem Mol Toxicol"},{"issue":"23","key":"10.1016\/j.jare.2021.10.004_b0245","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.3748\/wjg.v24.i23.2468","article-title":"Dynamic alterations in the gut microbiota and metabolome during the development of methionine-choline-deficient diet-induced nonalcoholic steatohepatitis","volume":"24","author":"Ye","year":"2018","journal-title":"World J Gastroenterol"},{"issue":"2","key":"10.1016\/j.jare.2021.10.004_b0250","doi-asserted-by":"crossref","first-page":"308","DOI":"10.3390\/ijms20020308","article-title":"Intestinal microbiota protects against MCD diet-induced steatohepatitis","volume":"20","author":"Schneider","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"9","key":"10.1016\/j.jare.2021.10.004_b0255","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.7150\/thno.18290","article-title":"Gut microbiota-mediated personalized treatment of hyperlipidemia using berberine","volume":"7","author":"Wang","year":"2017","journal-title":"Theranostics"},{"issue":"1","key":"10.1016\/j.jare.2021.10.004_b0260","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/jcph.1496","article-title":"Effects of upadacitinib coadministration on the pharmacokinetics of sensitive Cytochrome P450 probe substrates: a study with the modified cooperstown 5+1 cocktail","volume":"60","author":"Mohamed","year":"2020","journal-title":"J Clin Pharmacol"},{"issue":"11","key":"10.1016\/j.jare.2021.10.004_b0265","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.3390\/molecules22111994","article-title":"Influence of Shenxiong glucose injection on the activities of Six CYP isozymes and metabolism of warfarin in rats assessed using probe cocktail and pharmacokinetic approaches","volume":"22","author":"Sun","year":"2017","journal-title":"Molecules"},{"key":"10.1016\/j.jare.2021.10.004_b0270","doi-asserted-by":"crossref","unstructured":"Turpault S, Brian W, Van Horn R, Santoni A, Poitiers F, Donazzolo Y et al. Pharmacokinetic assessment of a five-probe cocktail for CYPs 1A2, 2C9, 2C19, 2D6 and 3A, Br J Clin Pharmacol 2009;928\u201335. doi:10.1111\/j.1365-2125.2009.03548.x.","DOI":"10.1111\/j.1365-2125.2009.03548.x"},{"key":"10.1016\/j.jare.2021.10.004_b0275","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2019\/1356264","article-title":"Influences of corydalis decumbens on the activities of CYP450 enzymes in rats with a cocktail approach","volume":"2019","author":"Cheng","year":"2019","journal-title":"Biomed Res Int."},{"key":"10.1016\/j.jare.2021.10.004_b0280","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2018\/1467143","article-title":"Influences of oldenlandia diffusa on the CYP450 activities in rats using a cocktail method by UHPLC-MS\/MS","volume":"2018","author":"Lin","year":"2018","journal-title":"Biochem Res Int"},{"key":"10.1016\/j.jare.2021.10.004_b0285","doi-asserted-by":"crossref","unstructured":"Paolini M, Biagi GL, Bauer C, Cantelli-Forti G. Cocktail strategy: complications and limitations, J Clin Pharmacol 1993;1011\u20132. doi:10.1002\/j.1552-4604.1993.tb01936.x.","DOI":"10.1002\/j.1552-4604.1993.tb01936.x"},{"issue":"4","key":"10.1016\/j.jare.2021.10.004_b0290","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0009-9236(97)90114-4","article-title":"Validation of the five-drug \u201cPittsburgh cocktail\u201d approach for assessment of selective regulation of drug-metabolizing enzymes","volume":"62","author":"Frye","year":"1997","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jare.2021.10.004_b0295","doi-asserted-by":"crossref","unstructured":"Fan L, Zhao X, Tong Q, Zhou X, Chen J, Xiong W et al. Interactions of Dihydromyricetin, a Flavonoid from Vine Tea (Ampelopsis grossedentata) with Gut Microbiota, J Food Sci 2018;1444\u20131453. doi: 10.1111\/1750-3841.14128.","DOI":"10.1111\/1750-3841.14128"},{"key":"10.1016\/j.jare.2021.10.004_b0300","doi-asserted-by":"crossref","unstructured":"Lange ME, Uwiera RRE, Inglis GD. Housing gnotobiotic mice in conventional animal facilities. Curr Protoc Mouse Biol 2019;e59. doi: 10.1002\/cpmo.59.","DOI":"10.1002\/cpmo.59"},{"issue":"10","key":"10.1016\/j.jare.2021.10.004_b0305","doi-asserted-by":"crossref","first-page":"751","DOI":"10.2165\/00003088-200241100-00005","article-title":"Enterohepatic circulation: physiological, pharmacokinetic and clinical implications","volume":"41","author":"Roberts","year":"2002","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"10.1016\/j.jare.2021.10.004_b0310","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1016\/0002-9378(90)90555-L","article-title":"Factors affecting the enterohepatic circulation of oral contraceptive steroids","volume":"163","author":"Orme","year":"1990","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.jare.2021.10.004_b0315","doi-asserted-by":"crossref","unstructured":"Byrne CD, Targher G. NAFLD: a multisystem disease, J Hepatol 2015;S47-64. doi: 10.1016\/j.jhep.2014.12.012.","DOI":"10.1016\/j.jhep.2014.12.012"}],"container-title":["Journal of Advanced Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2090123221002009?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2090123221002009?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:54:01Z","timestamp":1761857641000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2090123221002009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":63,"alternative-id":["S2090123221002009"],"URL":"https:\/\/doi.org\/10.1016\/j.jare.2021.10.004","relation":{},"ISSN":["2090-1232"],"issn-type":[{"value":"2090-1232","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gut microbiota and host Cyp450s co-contribute to pharmacokinetic variability in mice with non-alcoholic steatohepatitis: Effects vary from drug to drug","name":"articletitle","label":"Article Title"},{"value":"Journal of Advanced Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jare.2021.10.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V. on behalf of Cairo University.","name":"copyright","label":"Copyright"}]}}